ORIC Pharmaceuticals Inc (ORIC)
7.67
-0.41
(-5.07%)
USD |
NASDAQ |
Apr 25, 16:00
7.67
0.00 (0.00%)
After-Hours: 17:19
ORIC Pharmaceuticals Research and Development Expense (Annual): 85.17M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 85.17M |
| December 31, 2022 | 61.68M |
| December 31, 2021 | 56.86M |
| Date | Value |
|---|---|
| December 31, 2020 | 35.92M |
| December 31, 2019 | 22.84M |
| December 31, 2018 | 19.03M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
22.84M
Minimum
2019
85.17M
Maximum
2023
52.50M
Average
56.86M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Geron Corp | 125.05M |
| Verastem Inc | 61.36M |
| Karyopharm Therapeutics Inc | 138.75M |
| Syndax Pharmaceuticals Inc | 163.03M |
| Arvinas Inc | 379.70M |